Fatality as 2 people fall from overpass in CBD
Police are investigating how the people came to fall from the Western Distributor onto Harbour Street at about 9.45am.
A man and a woman, both believed to be in their 40s, died at the scene.
'Officers from Sydney City Police Area Command have established a crime scene and have commenced an investigation into the circumstances surrounding the incident,' NSW Police said in a statement.
Two southbound lanes of the Harbour Bridge have been closed.
Authorities also closed off Harbour Street in the Sydney CBD to southbound traffic.
The Transport Management Centre has urged motorists to allow extra time due to the incident.
'Southbound motorists should continue on the Western Distributor, before taking the Harris Street off-ramp, Harris Street, William Henry Street and Pier Street to access Harbour Street and the city's south,' the centre said.
Don't go it alone. Please reach out for help.
Lifeline: 13 11 14 or lifeline.org.au
Beyond Blue: 1300 22 4636 or beyondblue.org.au
Beyond Blue's coronavirus support service: 1800 512 348 or coronavirus.beyondblue.org.au
Kids Helpline: 1800 55 1800 or kidshelpline.com.au
Headspace: 1800 650 890 or headspace.org.au
Are you anxious? Take the Beyond Blue quiz to see how you're tracking and whether you could benefit from support
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
5 hours ago
- Newsweek
Newborn Was 'Normal Baby'—Then 5 Months Later Everything Changes
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Two U.K. parents who welcomed their newborn into the world had no idea their lives would change just a few months later. Conor Cross, 33, told Newsweek that he and Meredith Bradley, 31, thought the hardest part of their journey was behind them when they had their baby boy Reggie on September 28, 2024. The pregnancy had been complicated—marked by abnormal scan results; talk of possible termination; and a diagnosis of hypospadias, a congenital condition affecting the genitals. From left: Conor Cross holds newborn son, Reggie Cross in hospital; and father and son are pictured together months later. From left: Conor Cross holds newborn son, Reggie Cross in hospital; and father and son are pictured together months later. @conorruns But, after months of monitoring, Reggie was born "a normal baby," sleeping soundly, smiling and charming everyone he met. Then, just before Reggie turned 5 months, everything changed. Even before birth, Conor and Meredith knew he would need medical care. A raised nuchal translucency at the 12-week scan triggered a battery of tests, including a CVS, to rule out genetic syndromes. Reggie was cleared but monitored monthly. By birth, he had not only hypospadias but also undescended testes—raising the possibility he could have both male and female reproductive organs. Testing confirmed that he was genetically male. Soon after, another hurdle appeared: a recurring inguinal hernia that led to frequent hospital visits, including spending Christmas Day in the emergency room. Surgery in February 2025 to repair the hernia and bring down one testicle went smoothly, and Conor hoped his son's crying, discomfort and swelling would end. But the problems didn't stop. "Reggie became unsettled, [he] stopped taking his milk and the swelling didn't improve," Conor said. Reggie's eyes were swollen almost daily. The couple were desperate for answers, but doctors dismissed their concerns. "The response was that they didn't know what they'd be referring him for," Conor said. "It felt like we were going in circles, trying to convince people that something wasn't right." On March 1, after weeks of worsening symptoms, Conor pushed for further testing at Accident & Emergency (A & E). Blood work finally revealed the truth: Reggie was in complete kidney failure. By the next morning, they were rushed to Great Ormond Street Hospital in London via ambulance. At GOSH, doctors diagnosed Reggie with Stage V chronic kidney disease (CKD5). His kidneys were so damaged that they posed a cancer risk if not removed before his first birthday. He was immediately placed on peritoneal dialysis, running from 7 p.m. to 7 a.m. daily. Further genetic investigation led to a diagnosis of Denys-Drash syndrome, a rare condition linking his kidney failure with other medical issues. "Although emotions were high and we wanted answers, we had to let the life of our baby go into their hands," Conor said. "Anyone who knows GOSH knows that he is in the best place [but] even five months on, we don't know everything." The hospital's support extended beyond Reggie's treatment. The family has received financial help, free accommodation, food vouchers and funding for a shed to store Reggie's medications. Charities such as Great Ormond Street Hospital Charity and Kidney Care UK stepped in to make daily life more manageable. Grateful for the care they received, Conor decided to give back—by taking on a half marathon, despite never having run before. "I wanted to do something that would be challenging," he said. "I also wanted to show people that, if there is something in life that you want to do, then do it. Life is too short, and time will not slow down just because Reggie is going through a difficult time." Conor's first race will be the Chelmsford Half Marathon in October 2025, with a London Marathon spot secured for 2026. Reggie, now nearly 1 year old but still in 3-to-6-month clothes, remains "the happiest boy ever," according to his dad. Reggie faces the removal of both kidneys in September, followed by years of dialysis until he is big enough for a transplant at age 3 or 4. Through his updates on TikTok (@conorruns), Conor hopes to reassure parents—especially those facing medical uncertainty. "Don't feel pressured into living up to other people's expectations," he said. Conor, who is now a single father, also wants other families in similar situations to know they are not alone. "Mothers out there are just pure superheroes. For the dads, especially single dads like me, I want to inspire them by sharing my fitness journey." "I thought running would have been something I did just to raise money for these amazing charities, but, in fairness, it has saved me from going down a dark path," Conor added. "Starting something new is the hardest part, but you will fully understand how helpful that one thing can be just by doing it."
Yahoo
10 hours ago
- Yahoo
Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)
Radiopharm Theranostics Limited (NASDAQ:RADX) is among the 12 Best Australian Stocks to Buy Right Now. The company recently announced receiving Investigational New Drug (IND) approval from the FDA to begin a Phase 1 therapeutic clinical study to target B7H3 with Betabart (RV-01). A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products. The Lu-177-B7H3 monoclonal antibody is the first in class targeted radiopharmaceutical that is being developed against the 4lg type of B7H3. Radiopharm Theranostics Limited (NASDAQ:RADX) believes it has the potential to become a highly differentiated drug for treating individuals with aggressive solid tumors. The company says it is on track to initiate the first-in-human study during the fourth quarter of this calendar year. Findings from recent preclinical studies have shown that RV-01 exhibits hepatic clearance, which allows the isotope enough time to target tumors, while also potentially reducing adverse effects such as hematological toxicities. Moreover, these monoclonal antibodies are cleared by the liver, unlike peptides and small molecules. This, coupled with the shortened half-life of RV-01, makes this agent stand out compared to other monoclonal antibodies and targeted radiotherapeutics with a renal excretion pathway. Radiopharm Theranostics Limited (NASDAQ:RADX) is an Australia-based clinical-stage radiotherapeutics firm developing innovative radiopharmaceutical products for therapeutic and diagnostic applications in areas of high unmet medical need. While we acknowledge the potential of RADX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea
Incannex Healthcare Inc. (NASDAQ:IXHL) is among the 12 Best Australian Stocks to Buy Right Now. On August 8, the company announced positive new patient-reported outcomes from participants in its RePOSA Phase 2 trial of IHL-42X to treat obstructive sleep apnoea (OSA). A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The new insights were collected through exit interviews, in line with FDA's guidance on Patient-Focused Drug Development (PFDD). The results build on already compelling data to reinforce the potential of IHL-42X to improve sleep quality, cognitive function, and daily life. Incannex Healthcare Inc. (NASDAQ:IXHL) said that 57.6% of the respondents reported an improvement in their OSA, of which 89.5% described it as a meaningful change to their lives. Some of the reported benefits include better sleep quality, reduced sleepiness during the daytime, feeling fresh in the morning, and other cognitive and daily-life improvements. Joel Latham, President and CEO of Incannex Healthcare Inc. (NASDAQ:IXHL) stated the following on the findings: 'Our recent Phase 2 results for IHL-42X exceeded expectations. In some patients, we observed reductions in AHI of up to 83%, which is an extraordinary outcome and a powerful signal of the drug's potential. We believe the findings from the patient exit interviews underscore that these improvements are not just clinical—they are translating into meaningful, positive changes in patients' daily lives. This reinforces our belief that IHL-42X has the potential to significantly shift the treatment paradigm for OSA.' Incannex Healthcare Inc. (NASDAQ:IXHL) is a clinical-stage pharmaceutical company developing medicines to treat chronic conditions, including obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis. While we acknowledge the potential of IXHL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
